Hold at $402: mandatory hedge overlay required, add triggers at $413 close and confirmed EPS recovery
HOLD maintained at $402 with convergent all-analyst agreement; mandatory $400/$365 put spread hedge (25% of residual, 60-90 DTE) required per 2026-08-05 lesson or rating mechanically downgrades to Underweight; base case $420 (60% probability), bull $445 (15%), bear $385 (25%); add triggers at $413 close on ≥5M volume and 2nd consecutive EPS ≥$6.50; closing-basis stop at $399.73 (lower Bollinger); 12-month probability-weighted expected value ~$415 supports Hold not Buy.
| Position | Action |
|---|---|
| Current residual position at $402 | Maintain current position size; do not add |
| Daily close >$413 on volume ≥5M shares → scale in 25% of incremental size | Add 25% incremental |
| 2nd consecutive quarter EPS ≥$6.50 | Scale in another 25% of incremental size |
| Daily close >$418 | Final tranche - full position |
| Rally to $418-$436 zone without earnings confirmation | Trim 20-25% of position - opportunistic |
| Close below $395 on expanding volume | Trim 25-33% immediately to Underweight |
| Close below $385 on volume | Exit residual entirely |
The current pullback to $402 represents a "fat-pitch" entry opportunity, not a warning sign, as technical weakness is a higher-low setup within a confirmed structural uptrend, the Q1 2026 EPS print already confirmed the operating margin inflection is happening now rather than years away, and the forward PE of 17.93x represents the cheapest entry point an investor will ever get if the bear's own "multi-year repair" thesis is correct.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 410.70 | bearish |
| close_50_sma | 413.31 | bearish |
| close_200_sma | 343.39 | bullish |
| macd | -2.64 | bearish |
| macdh | -2.79 | bearish |
| rsi | 41.47 | bearish |
| boll | 418.10 | bearish |
| boll_ub | 436.47 | bearish |
| boll_lb | 399.73 | bullish |
| atr | 11.49 | neutral |
Support: 399.73 · 395 · 400 · 390.48 · 375 · 380 · 343.39 | Resistance: 410 · 413 · 418.1 · 428 · 436 · 445
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Scale in 25% of incremental position
↩ rebuts: “Bear's technical weakness signal is a 'wait' moment”
EV: +19% to +27% (12-month); +14.4% (6-month); +8.5% (3-month) · concedes: Operating margin compressed from 8.71% peak in 2023 to 7.13% TTM is a real data point; Management itself calls margin repair 'multi-year'; Warren/regulatory headlines create short-term noise; Trailing PE of 30.29x appears elevated vs peers; TTM EPS of $13.28 reflects trough earnings; Buyback program paused through 2025 reset, expected to return by mid-2027
The stock at $402 presents unfavorable risk/reward asymmetry with ~3.5% expected 6-month return (roughly equal to the dividend yield), requiring multiple favorable outcomes simultaneously while a 35% probability of $12+ downside looms from lower Bollinger Band breakdown.
EV: ~+3.5% over 12 months (probability-weighted: 0.30 × $480 + 0.45 × $410 + 0.25 × $390 - $402 = +$14) · concedes: Lower Bollinger Band test could hold and produce bounce to $418 (+4%); Two consecutive quarters of EPS ≥ $6.50 would confirm recovery trend; Resolution of DOJ/Amedisys case with no material divestitures would clear regulatory fog; Buyback resumption would signal management confidence
→ vs conservative: Waiting for RSI 30 at ~$390 is chasing, not investing; the 200 SMA at $343 provides 17% structural floor making the ~2.5% risk minimal compared to the asymmetry of the setup
→ vs conservative: Early June example: same indicator readings at $375 preceded rally to $436; waiting for confirmation misses the move
→ vs neutral: Using static 17.9x PE ignores the 69% earnings recovery trajectory; at $25 EPS with stock at $402, forward PE compresses to 16x with 2.27% yield, which is cheap for a compounder with 50M members and $16B FCF
→ vs neutral: Waiting for $413+ confirmation means buying into the 50 SMA and Bollinger midline resistance where overhead supply will cap the stock after reclaim
→ vs neutral: Missing StockTwits sentiment data is a non-event; UNH trades on Medicare Advantage rate notices and institutional positioning, not retail euphoria
UNH is testing the lower Bollinger Band at $399.73 after declining ~7.8% from the July 2026 peak. Short-term momentum is bearish (price below all short-term MAs, MACD negative at -2.64, RSI neutral-bearish at 41.47) but the structural uptrend remains intact (200 SMA at $343.39, ~17% below price). Critical support at $399.73; resistance at $410-413 (10 EMA/50 SMA) and $418.10 (20 SMA/Bollinger midline). ATR of $11.49 suggests position sizing should account for ~3% downside risk to $390. VWMA data unavailable and excluded per protocol.
Market Cap
$365.2B
52-Week High
$461.62
52-Week Low
$253.67
Beta
0.63
Dividend Yield
2.27%
Trailing PE
30.29x
Forward PE
17.93x
PEG Ratio
1.26
Price to Book
3.49x
EPS (TTM)
$13.28
Forward EPS
$22.44
Book Value per Share
$115.36
Revenue (TTM)
$450,129M
Net Income (TTM)
$14.12B
Gross Margin
19.5%
Operating Margin
7.13%
Net Profit Margin
3.14%
ROE
14.15%
ROA
4.38%
Total Assets
$312.6B
Total Debt
$77.92B
Long-Term Debt
$71.44B
Cash and Equivalents
$28.00B
Net Debt
$49.92B
Stockholders' Equity
$97.88B
Debt to Equity
69.2
Working Capital
-$22.99B
Goodwill
$110.5B
Tangible Book Value
-$32.72B
Operating Cash Flow (2025)
$19.70B
Free Cash Flow (2025)
$16.08B
Dividends Paid (2025)
$7.92B
Buybacks (2025)
$5.55B
Revenue Growth (3-yr CAGR)
~11.3%
Q1 2026 Revenue
$111,721M
Q1 2026 Net Income
$6,280M
Q1 2026 EPS
$6.90
Q1 2026 Operating Margin
8.05%
Q4 2025 Net Income
$10M
Q4 2025 EPS
$0.01
Strengths
Concerns
UNH is the highest-quality managed-care franchise in the world, but 2024-2025 earnings were disrupted by industry-wide Medicare Advantage cost pressure and one-off operational issues including the Change Healthcare cyberattack. The Q1 2026 results (EPS $6.90 vs. Q4 2025's $0.01) confirm an earnings inflection is underway. Valuation at forward PE ~18x is reasonable for a best-in-class compounder with defensive characteristics (beta 0.63) and a 2.27% dividend yield. The company generates $16.08B in annual free cash flow that comfortably covers the $7.92B dividend. Principal near-term risks include MLR trajectory, CMS rate decisions, regulatory outcomes, DOJ antitrust scrutiny, and $110.5B goodwill concentration. For investors with a 2-3 year horizon, the current setup offers an attractive entry into a defensive compounder recovering from a cyclical operational shock.
Macro: Fed policy: Polymarket 86% probability of no Fed rate cuts in 2026 (rising, +3.2pp week-over-week). Recession odds: US 8% by end of 2026 (-2.0pp), UK 18%, Japan 33%. Market regime: back-to-back equity declines into CPI print with growth sectors hit and oil bid; Nasdaq/semis leading Tuesday 8/11 recovery. Healthcare is the dominant anti-AI defensive trade. Note: FRED macroeconomic data (CPI, Fed funds, unemployment, 10Y, VIX) unavailable; macro characterization grounded in news tone and Polymarket-implied probabilities only — no fabricated CPI, rate, or unemployment figures.